Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Merck (MSD International GmbH): worldwide exclusive license for ruzasvir (Dec 2021); milestones (incl. $5M on first C-BEYOND patient, Apr 2025) + tiered royalties high single digits to mid-teens
Indications
Hepatitis C virus (HCV)(Phase 3)
Catalysts
— early first quarter 2027
— second quarter 2027
Status note Lead program: fixed-dose combination for HCV. C-BEYOND (US/Canada) reported topline July 2026; C-FORWARD (ex-North America, ~120 sites/17 countries) completed enrollment June 2026; NDA submission targeted second quarter 2027 (pending positive C-FORWARD data).
AT-587
Phase 1 · ActiveModality: oral antiviral
Target RdRp
Indications
Hepatitis E virus (HEV)(Phase 1)
Status note Potential first direct-acting antiviral for HEV, focused on chronic HEV in immunocompromised patients. Phase 1 first-in-human trial in healthy volunteers initiated July 2026.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.